The top 6 potential anti-HCC core targets, i.e., EGFR, CASP3, ESR1, MAPK3, ERBB2, and CCND1, were chosen for molecular docking studies, with key active phytochemicals described in Section 2.6. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.